Geoff is chief executive officer of Speciality European Pharma Ltd and a non-executive director of Galapagos NV. He has over 25 years of experience within the pharmaceutical and biotechnology industries. He has worked for Smith and Nephew, Roche, Xenova Group plc, Elan and Biofocus plc. He has an outstanding record of deal making, ranging from product and technology licensing to mergers and acquisitions. He is also Chairman of the AIM Compliance Committee.

With over 15 years’ experience in the pharmaceutical industry, Tim has held senior commercial positions at Pfizer and SmithKline Beecham both domestically and internationally. His most recent roles were with Elan where he was general manager for Ireland and vice president, international marketing. During his time at Elan, Tim was instrumental in the establishment, significant growth and ultimate successful divestment of their European business.

Nigel spent over nine years at KPMG, latterly as senior manager, prior to moving into industry in 1996. He has over ten years’ experience working in the pharmaceutical and life sciences sectors, where he has held senior financial positions at Life Sciences International plc and at Almedica International Inc where for five years he was chief financial officer.

Ann has over 25 years’ experience in the pharmaceutical industry, where she has held senior positions in operations, quality and technical management for Glaxo Pharmaceuticals, Evans Medical Ltd and Medeva Pharma Ltd. Ann holds a BSc with Honours in Biology and has a Diploma in Company Direction. She has responsibility for both regulatory and technical operations within IS Pharma.

Currently non-executive chairman of Noble VCT plc and a non-executive director of Bluehone AiM VCT plc, John is also a non-executive director or chairman of a number of private companies and was, prior to these appointments, an executive director of Noble Fund Managers. John’s earlier career was in the City and included posts as a director of Singer & Friedlander Holdings and managing director of Henry Ansbacher & Co. He is Chairman of the Audit Committee.

With over 25 years’ experience in pharmaceuticals and devices, Peter left Napp Laboratories to form Cambridge Laboratories in 1987, leading it to profitability and ultimately to international status. In 1996 he formed High Crane Limited, focusing on management consultancy and in 2001 co-founded Acorus Therapeutics Limited, to provide niche hospital orientated pharmaceutical products and medical devices. He is Chairman of the Remuneration Committee.